← Leaderboards
Kurt R. Brunden
University Of Pennsylvania
$9,865,188
Attributed
$15,292,231
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,292,231 · 5
By mechanism
U01$8,523,247 · 2
R01$4,523,437 · 2
RF1$2,245,547 · 1
Top collaborators
- Carlo Ballatore11 shared
- Conor Caffrey2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Carlo Ballatore$3,618,196
- Garret A Fitzgerald$242,218,424
- Amos B Smith$26,356,961
- Douglas Hamilton Smith$26,977,456
- Jeffrey S Phillips$4,889,167
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNeuronsS DiseaseNerve DegenerationBrainTransgenic MiceSafetyDoseMouse ModelProgramsDrug CandidateEvaluationIn VitroLeadTauopathiesDrug KineticsNeurodegenerative DisordersMicrotubulesStructureTau ProteinsPharmaceutical PreparationsMicrotubule Stabilizing AgentEpothilone DNeuron Loss
Grant awards (19)
Development of a MT-stabilizing agent for the treatment of tauopathies$2,250,355
U01 · FY2025 · AG
Development of a MT-stabilizing agent for the treatment of tauopathies$2,309,108
U01 · FY2024 · AG
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$746,084
U01 · FY2022 · AG · contact PI
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$311,482
U01 · FY2022 · AG · contact PI
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$851,784
U01 · FY2021 · AG · contact PI
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$159,949
U01 · FY2021 · AG · contact PI
Identification of small molecule inhibitors of tau pathology utilizing a novel primary neuronal assay.$2,245,547
RF1 · FY2020 · AG · contact PI
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$946,116
U01 · FY2020 · AG · contact PI
Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies$948,369
U01 · FY2019 · AG · contact PI
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$455,558
R01 · FY2017 · AG · contact PI
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$464,643
R01 · FY2016 · AG · contact PI
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$453,496
R01 · FY2015 · AG
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$478,571
R01 · FY2014 · AG
Brain-Penetrant Thromboxane Receptor Antagonists for Alzheimer's Disease Therapy$438,699
R01 · FY2014 · AG · contact PI
Orally-absorbed, small molecule microtubule-stabilizers for tauopathy treatment$478,571
R01 · FY2013 · AG
Brain-Penetrant Thromboxane Receptor Antagonists for Alzheimer's Disease Therapy$448,760
R01 · FY2013 · AG · contact PI
Brain-Penetrant Thromboxane Receptor Antagonists for Alzheimer's Disease Therapy$460,882
R01 · FY2012 · AG · contact PI
Brain-Penetrant Thromboxane Receptor Antagonists for Alzheimer's Disease Therapy$446,691
R01 · FY2011 · AG · contact PI
Brain-Penetrant Thromboxane Receptor Antagonists for Alzheimer's Disease Therapy$397,566
R01 · FY2010 · AG · contact PI